Bentley, R, Hardy, LJ, Scott, LJ et al. (3 more authors) (2021) Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. Expert Opinion on Investigational Drugs, 30 (10). pp. 1057-1069. ISSN 1354-3784
Abstract
Introduction
Atrial fibrillation is the most frequently diagnosed cardiac arrhythmia globally and is associated with ischemic stroke and heart failure. Patients with atrial fibrillation are typically prescribed long-term anticoagulants in the form of either vitamin K antagonists or non-vitamin K antagonist oral anticoagulants; however, both carry a potential risk of adverse bleeding.
Areas Covered
This paper sheds light on emerging anticoagulant agents which target clotting factors XI and XII, or their activated forms – XIa and XIIa, respectively, within the intrinsic coagulation pathway. The authors examined data available on PubMed, Scopus, and the clinical trials registry of the United States National Library of Medicine (www.clinicaltrials.gov).
Expert Opinion
Therapies targeting factors XI or XII can yield anticoagulant efficacy with the potential to reduce adverse bleeding. Advantages for targeting factor XI or XII include a wider therapeutic window and reduced bleeding. Long-term follow-up studies and a greater understanding of the safety and efficacy are required. Atrial fibrillation is a chronic disease and therefore the development of oral formulations is key.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
Keywords: | Anticoagulant, antibody, antisense oligonucleotide, atrial fibrillation, clotting factor, intrinsic pathway, clinical trial, novel, small molecule, stroke, thromboembolism, fxi, fxii, therapeutics |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM) > Discovery & Translational Science Dept (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 30 Jun 2022 14:36 |
Last Modified: | 30 Jun 2022 14:36 |
Status: | Published |
Publisher: | Taylor & Francis |
Identification Number: | 10.1080/13543784.2021.1897786 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:188277 |